MX9400177A - Eteres de o-aril de (+)-morfinanos empleados como agentes neuroprotectores, proceso para su manufactura y composicion farmaceutica que los contiene. - Google Patents

Eteres de o-aril de (+)-morfinanos empleados como agentes neuroprotectores, proceso para su manufactura y composicion farmaceutica que los contiene.

Info

Publication number
MX9400177A
MX9400177A MX9400177A MX9400177A MX9400177A MX 9400177 A MX9400177 A MX 9400177A MX 9400177 A MX9400177 A MX 9400177A MX 9400177 A MX9400177 A MX 9400177A MX 9400177 A MX9400177 A MX 9400177A
Authority
MX
Mexico
Prior art keywords
alkyl
formula
aryl
hydrogen
group
Prior art date
Application number
MX9400177A
Other languages
English (en)
Inventor
Erno Mohacsi
Jay Philip O'brien
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX9400177A publication Critical patent/MX9400177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

El presente invento se refiere al empleo de compuestos de la fórmula 1: y sus sales farmacéuticamente aceptables, para la preparación de un medicamento para reducir efectos adversos de lesión tóxica a neuronas del sistema nervioso central, particularmente en donde la lesión a neuronas del sistema nervioso central está asociado con isquemia, hipoxia, hipoglicemia, epilepsia, enfermedad de Huntington o enfermedad de Alzheimer, o para tratar convulsiones.
MX9400177A 1993-01-06 1994-01-03 Eteres de o-aril de (+)-morfinanos empleados como agentes neuroprotectores, proceso para su manufactura y composicion farmaceutica que los contiene. MX9400177A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US113593A 1993-01-06 1993-01-06

Publications (1)

Publication Number Publication Date
MX9400177A true MX9400177A (es) 1994-07-29

Family

ID=21694554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9400177A MX9400177A (es) 1993-01-06 1994-01-03 Eteres de o-aril de (+)-morfinanos empleados como agentes neuroprotectores, proceso para su manufactura y composicion farmaceutica que los contiene.

Country Status (23)

Country Link
EP (1) EP0612730B1 (es)
JP (1) JP2501298B2 (es)
KR (1) KR940018094A (es)
CN (1) CN1097006A (es)
AT (1) ATE154931T1 (es)
AU (1) AU681601B2 (es)
BR (1) BR9400021A (es)
CA (1) CA2110337A1 (es)
CZ (1) CZ2294A3 (es)
DE (1) DE69311887T2 (es)
DK (1) DK0612730T3 (es)
ES (1) ES2105061T3 (es)
FI (1) FI940041A (es)
GR (1) GR3024891T3 (es)
HU (2) HUT66061A (es)
IL (1) IL108247A (es)
MX (1) MX9400177A (es)
NO (1) NO940028D0 (es)
NZ (1) NZ250580A (es)
PL (1) PL175365B1 (es)
TW (1) TW264473B (es)
UY (1) UY23706A1 (es)
ZA (1) ZA939806B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9522176D0 (en) * 1995-10-30 1996-01-03 Iaf Biochem Int Morphinan derivatives having neuroprotective activity
DE69739561D1 (de) * 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
FR2752163B1 (fr) * 1996-08-12 1998-10-30 Pf Medicament Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington
GB9706753D0 (en) * 1997-04-03 1997-05-21 Pharmacia & Upjohn Spa Aralkoxy-morphinan derivatives
KR100425881B1 (ko) * 2001-03-14 2004-04-03 고광호 신규한 몰피난 유도체
EP1506174B1 (en) * 2002-05-17 2015-09-30 Taiwanj Pharmaceuticals Co., Ltd. Use of naltrexone for treating kidney and liver damage
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
US20040204862A1 (en) 2003-04-11 2004-10-14 Wainer Irving W. Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
EP2398805A1 (en) * 2009-02-23 2011-12-28 Mallinckrodt LLC (+)-morphinanium quaternary salts and processes for their production
CN103044327B (zh) * 2013-01-07 2014-12-17 苏州立新制药有限公司 一种右美沙芬的制备方法
SG10201901242PA (en) * 2014-09-14 2019-03-28 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2016138103A1 (en) * 2015-02-25 2016-09-01 Alkermes, Inc. Treatments for alzheimer's related diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI773636A (fi) * 1976-12-06 1978-06-07 Hoffmann La Roche Nya fenylderivat
US4113729A (en) * 1976-12-06 1978-09-12 Hoffmann-La Roche Inc. 3-Phenoxymorphinans and derivatives thereof
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury

Also Published As

Publication number Publication date
PL301784A1 (en) 1994-07-11
AU681601B2 (en) 1997-09-04
BR9400021A (pt) 1994-07-26
KR940018094A (ko) 1994-08-16
PL175365B1 (pl) 1998-12-31
DE69311887T2 (de) 1998-01-15
CA2110337A1 (en) 1994-07-07
HUT66061A (en) 1994-09-28
DE69311887D1 (de) 1997-08-07
IL108247A (en) 1998-02-22
ATE154931T1 (de) 1997-07-15
NZ250580A (en) 1996-07-26
NO940028L (es) 1994-07-07
GR3024891T3 (en) 1998-01-30
ES2105061T3 (es) 1997-10-16
TW264473B (es) 1995-12-01
ZA939806B (en) 1994-07-06
EP0612730B1 (en) 1997-07-02
FI940041A0 (fi) 1994-01-05
FI940041A (fi) 1994-07-07
EP0612730A1 (en) 1994-08-31
UY23706A1 (es) 1994-06-05
JP2501298B2 (ja) 1996-05-29
DK0612730T3 (da) 1998-02-02
AU5280793A (en) 1994-07-14
HU211290A9 (en) 1995-11-28
JPH06316564A (ja) 1994-11-15
CZ2294A3 (en) 1994-07-13
NO940028D0 (no) 1994-01-04
HU9400002D0 (en) 1994-05-30
IL108247A0 (en) 1994-04-12
CN1097006A (zh) 1995-01-04

Similar Documents

Publication Publication Date Title
MX9400177A (es) Eteres de o-aril de (+)-morfinanos empleados como agentes neuroprotectores, proceso para su manufactura y composicion farmaceutica que los contiene.
OA09391A (en) "Isoxazole derivatives".
ES2066000T3 (es) Compuestos derivados de pirimidinediona, metodo de produccion de los mismos y agentes antirritmicos que los contienen.
HU9301866D0 (en) Benzoxa-condensed-ring-compounds and medical preparatives containing these compounds and processes for production of these compounds and of pharmaceutical composition
DE69326395D1 (de) Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
YU224790A (sh) Aminokarbonil karbamati, sorodni fizostigminu/in postopek za njihovo pripravo in njihova uporaba kot zdravila
ATE67199T1 (de) Benzoxazin-derivate und verfahren zu ihrer herstellung.
BR9103665A (pt) Composicao inseticida e processo para a producao de um composto
NO305956B1 (no) Benzenderivat nyttig for ischemiske sykdommer
ES2084120T3 (es) Medicamentos para prevenir y tratar enfermedades del aparato circulatorio que contienen compuestos de espiro-3-heteroazolidina.
DE69016266D1 (de) Aminoketonverbindungen.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees